Development of immunotherapeutic strategies for the treatment of malignant neoplasia.
The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.
Talmadge
J E
JE
Smith Kline & French Laboratories, Research Development Division, King of Prussia, Pa.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
D000970:Antineoplastic Agents; D007155:Immunologic Factors